15.64
前日終値:
$15.73
開ける:
$15.1
24時間の取引高:
3.06M
Relative Volume:
1.38
時価総額:
$1.85B
収益:
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.9898
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-9.54%
1か月 パフォーマンス:
+14.24%
6か月 パフォーマンス:
+68.17%
1年 パフォーマンス:
+57.82%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARQT
Arcutis Biotherapeutics Inc
|
15.64 | 1.85B | 59.61M | -262.14M | -247.49M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-30 | 開始されました | H.C. Wainwright | Buy |
2024-08-28 | 開始されました | Jefferies | Buy |
2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
2022-09-07 | 開始されました | Needham | Buy |
2022-03-17 | 開始されました | Goldman | Buy |
2021-06-30 | 開始されました | Mizuho | Buy |
2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-11-09 | アップグレード | Goldman | Neutral → Buy |
2020-10-08 | 開始されました | Truist | Buy |
2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
2020-02-25 | 開始されました | Cowen | Outperform |
2020-02-25 | 開始されました | Goldman | Neutral |
2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - TradingView
Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com
Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com UK
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - Medical Marketing and Media
Arcutis Biotherapeutics shares jump - MSN
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India
What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow
Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian
Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com India
Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World
Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise
Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com India
Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock - Investing.com
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):